Business
Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026
SANTA CLARA, Calif., March 19, 2026--Agilent Technologies Inc. (NYSE: A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a foundati
About this update from Agilent Technologies, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":404,"url":"https://media.zenfs.com/en/business-wire.com/974fd209d5b0add3651ff06aa95a4ff4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zq_7sYIIymXNMiaEdCSszw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4OA--/https://media.zenfs.com/en/business-wire.com/974fd209d5b0add3651ff06aa95a4ff4","width":960,"height":388},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/4AFM0Nlm_AG4_1WbgR8J4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD04MDg-/https://media.zenfs.com/en/business-wire.com/974fd209d5b0add3651ff06aa95a4ff4","width":1000,"height":404}},"lazy":false},{"type":"text","content":"Expanded PD‑L1 indication and end‑to‑end digital pathology workflows support modern pathology practice","length":102,"tagName":"p"},{"type":"text","content":"SANTA CLARA, Calif., March 19, 2026--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a foundation for scalable, automation‑ready pathology laboratories.","length":574,"tagName":"p"},{"type":"text","content":"At USCAP 2026, Agilent will feature its continued expansion in oncology diagnostics, including a new PD‑L1 indication for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), reinforcing Agilent’s commitment to supporting biomarker‑driven precision oncology. This addition builds on Agilent’s established PD‑L1 portfolio and supports laboratories as testing needs evolve alongside increasingly complex therapeutic landscapes.","length":447,"tagName":"p"},{"type":"text","content":"Agilent will also demonstrate its progress in advancing end‑to‑end digital pathology workflows, designed to help laboratories improve efficiency, reproducibility, and confidence while scaling for future demand. These workflows integrate staining, imaging, and data management to support streamlined slide digitization, organization, and helping pathology ...